The development of subsensitivity to nebulized atropine sulfate.
Lucielle Mansfield, Taylor Vaughn, Robert W. Haverly, S. Ting
Abstract
Lucielle Mansfield, Taylor Vaughn, Robert W. Haverly, S. Ting
Abstract
Ten adult asthmatic subjects were tested for response to inhaled atropine sulfate before and after 3 weeks of inhaled atropine therapy. Four of the ten initial responders no longer responded after the 3 weeks. The mean FEV1 increase was 0.49 L before treatment and 0.30 L after treatment (P = .025). Subsensitivity to the effects of atropine develops, but may be limited to a subset of patients.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Ten adult asthmatic subjects were tested for response to inhaled atropine sulfate before and after 3 weeks of inhaled atropine therapy. Four of the ten initial responders no longer responded after the 3 weeks. The mean FEV1 increase was 0.49 L before treatment and 0.30 L after treatment (P = .025). Subsensitivity to the effects of atropine develops, but may be limited to a subset of patients.
Key concepts: Atropine, Atropine sulfate, Medicine, Anesthesia, Parasympatholytic, Internal medicine, Muscarinic acetylcholine receptor, Receptor